Ticker Details
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.
IPO Date:	June 1, 1998
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$190.95M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.26%
Avg Daily Range (30 D):	$0.07 | 3.13%
Avg Daily Range (90 D):	$0.07 | 2.98%

Institutional Daily Volume
Avg Daily Volume:	.37M
Avg Daily Volume (30 D):	.56M
Avg Daily Volume (90 D):	.76M

Trade Size
Avg Trade Size (Sh.):	257
Avg Trade Size (Sh.) (30 D):	107
Avg Trade Size (Sh.) (90 D):	147

Institutional Trades
Total Institutional Trades:	286
Avg Institutional Trade:	$1.6M
Avg Institutional Trade (30 D):	$1.59M
Avg Institutional Trade (90 D):	$1.27M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$4.65M
Avg Closing Trade (30 D):	$1.59M
Avg Closing Trade (90 D):	$1.27M
Avg Closing Volume:	622.3K

News

Mar 9, 2026 @ 10:00 AM Chiesi Global Rare Diseases and Protalix BioTherap... Source: Chiesi Global Rare Diseases / Protalix Biotherapeutics

Mar 26, 2025 @ 7:00 PM [Latest] Global Fabry Disease Treatment Market Siz... Source: Custom Market Insights

Jun 12, 2024 @ 3:45 PM Pluxee to acquire Cobee, an innovative Spanish dig... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee signe un accord pour l’acquisition d... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee firma un acuerdo para adquirir Cobee, empre... Source: Pluxee N.V

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.2	$.23	$-.07
Diluted EPS	$.19	$.22	$-.07
Revenue	$76.38M	$33.75M	$9.12M
Gross Profit	$53.44M	$29.62M	$4.5M
Net Income / Loss	$15.33M	$18.32M	$-5.5M
Operating Income / Loss	$19.79M	$21.15M	$-4.66M
Cost of Revenue	$22.94M	$4.13M	$4.62M
Net Cash Flow	$21.66M	$26.4M	$1.06M
PE Ratio

Splits
Dec 20, 2019	1:10
Jan 03, 2007	1:10